Benjamin Bakall, MD, PhD; Alex Young; Eamon N. Dreisbach; Anthony DeFino , 2025-05-06 16:28:00
SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, Benjamin Bakall, MD, PhD, discusses 2-year data from the TEASE-1 study investigating the safety and efficacy of gildeuretinol in patients with Stargardt disease.
The study met its primary endpoint, and patients who received gildeuretinol (Alkeus Pharmaceuticals) showed a significant reduction in growth of the area of atrophy.
“As a retina specialist treating patients with Stargardt disease, it’s been very frustrating that we haven’t had any effective tools and options for treating the areas of atrophy and vision loss,” Bakall said. “It’s my hope that this treatment may be a great tool for the future treatment of patients with Stargardt disease.”
Sources/Disclosures
Collapse
Bakall B, et al. Gildeuretinol slows progression of Stargardt disease: The TEASE 1 program. Presented at: Association for Research in Vision and Ophthalmology meeting; May 4-8, 2025; Salt Lake City.
Disclosures:
Bakall reports working at an investigative site sponsored by Alkeus Pharmaceuticals.
